品牌非專利市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類別、應用、分銷管道、地區和競爭格局分類，2021-2031年

全球品牌學名藥市場預計將從 2025 年的 2,624.5 億美元大幅成長至 2031 年的 3,788.7 億美元，複合年成長率為 6.31%。

這些產品與取得專利的原廠藥具有生物等效性，由非專利藥生產商以自有品牌名稱銷售。推動其發展的因素包括全球對經濟高效醫療保健日益成長的需求，以及慢性病盛行率不斷上升，而這些疾病需要價格合理、長期有效的治療方案。這些因素促使醫療服務提供者和保險公司優先考慮高效低成本的替代療法。新興經濟體醫藥市場的快速成長是這項擴張的關鍵促進因素。在這些國家，可支配收入的增加以及對品質有保證的藥品的偏好，使得患者和醫生更傾向於選擇品牌仿製非專利而非不知名的學名藥，尤其是那些監管體係被認為不穩定的學名藥。太陽製藥在新興市場的製劑銷售額也印證了這一趨勢，其在2024-2025會計年度的銷售額達到11.14億美元，年增7.0%。同時，專利到期為品牌非專利進入市場提供了重要機遇，使生產商能夠利用品牌知名度，以等效的治療方案贏得市場佔有率。默克的Keytruda就是一個典型的例子，在專利到期前，於2024年實現了295億美元的銷售額。美國FDA等監管機構也積極扶持新進者，核准在2025年批准87種新的學名藥上市。

市場促進因素

新興經濟體藥品市場的擴張，主要受可支配收入成長和消費者對品質保證藥品日益成長的偏好所驅動，這成為品牌學名藥行業的主要成長要素。在一些國家，非品牌學名藥的法律規範被認為不足，患者和醫生傾向於選擇品牌學名藥，因為品牌學名藥被認為更安全，是價格昂貴的專利藥和當地非品牌學名藥之間的折中選擇。這一趨勢也體現在這些地區主要製藥公司的財務業績中；太陽製藥工業有限公司（Sun Pharmaceutical Industries）報告稱，其在新興市場的產品銷售額在2024-2025會計年度達到11.14億美元，同比成長7.0%。同時，重磅藥物專利到期為進入品牌非專利市場提供了重要機會。隨著高價值專利藥的獨家銷售權到期，製藥商準備利用其已建立的品牌知名度，透過提供與原廠藥和普通仿製學名藥具有療效相當的替代藥物來獲取市場佔有率。這種盈利的局面的一個例子是，一種重要的抗癌藥物的專利保護即將到期。默克的Keytruda在2024年創造了295億美元的銷售額，專利到期後，這部分收入將成為主要目標。為了抓住這些變化帶來的機遇，監管機構仍然保留著促進新進入者的監管途徑。美國食品藥物管理局（FDA）在2025年核准了87種首次上市的學名藥，確保了專利到期的療法持續湧入全球市場。

市場挑戰

監管機構施加的巨大價格壓力和競爭性競標制度是限制市場擴張的主要因素。世界各國政府和支付者都在實施嚴格的成本控制策略，優先考慮盡可能降低採購成本，而非品牌差異化。在這種環境下，非品牌學名藥在採購過程中往往更受青睞，迫使品牌非專利生產商大幅降價以保持競爭力。這一趨勢正在系統性地削弱品牌非專利的高階動態，使生產商難以維持品牌推廣和行銷活動所需的利潤率。由此產生的財務壓力限制了市場參與者的獲利潛力，儘管市場需求旺盛。生產商被迫在極低的利潤率下運營，這阻礙了他們拓展產品組合和投資供應鏈韌性的能力。例如，可及藥品協會預測，到2024年，學名藥將占美國所有處方箋的90%，但僅佔藥品總支出的13.1%，這就說明了價值侵蝕的嚴重性。處方箋數量多而收入佔有率低的這種明顯不平衡，凸顯了嚴峻的經濟環境，直接限制了品牌學名藥產業的財務成長。

市場趨勢

在價格逆風和市場飽和的背景下，隨著製造商強化產品組合，策略性產業重組和併購正成為關鍵趨勢。透過收購目標資產，企業可以快速整合眼科和生物相似藥等高進入門檻產品，從而擴大業務規模，並確保即時收入來源，以抵消傳統學名藥利潤率的下降。這種非內部成長策略使企業能夠避免漫長的研發週期，獲得穩定的市場進入，並最佳化成本結構。據山德士公司稱，該公司於2024年3月完成了對Kohelas Biosciences旗下CIMERLI業務的收購，預付現金1.7億美元。此舉顯然旨在加強其眼科平台並利用其現有的商業基礎設施。同時，市場正加速從商品化的口服固態製劑轉向複雜的學名藥和生物相似藥。製造商正日益將資源投入生產難度更高的劑型，例如注射劑和吸入劑，這些劑型與標準學名藥相比，具有更大的定價權和更小的競爭。這種轉變不僅提高了盈利，也符合慢性病照護領域對專業療法日益成長的需求，而品牌價值在這一領域發揮決定性作用。 Amneel Pharmaceuticals 的報告顯示，2024 年 11 月，其學名藥部門的淨銷售額成長了 9%，達到 4.27 億美元，這便是該策略取得商業性成功的一個例證。這項業績主要得益於市場對新型複雜產品和生物相似藥的強勁接受度。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球品牌非專利市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物分類（烷化劑、抗代謝藥、荷爾蒙、抗高血壓藥、降血脂藥、抗憂鬱症、抗精神病藥、抗癲癇藥、其他）
  • 依應用領域（腫瘤科、心血管疾病科、神經系統疾病科、急性慢性疼痛科、消化系統疾病科、皮膚科等）
  • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美品牌非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲品牌非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區品牌非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲品牌非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美品牌非專利市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球品牌非專利市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global branded generics market is forecasted for substantial growth, escalating from USD 262.45 Billion in 2025 to USD 378.87 Billion by 2031, at a 6.31% CAGR. These products, bioequivalent to original patented drugs yet marketed under a proprietary name by generic manufacturers, are propelled by the increasing global demand for cost-effective healthcare and the rising prevalence of chronic diseases requiring affordable, long-term treatment solutions. These factors encourage healthcare providers and payers to prioritize therapeutically effective, lower-cost alternatives. A key driver for this expansion is the burgeoning pharmaceutical markets in emerging economies, where rising disposable incomes and a preference for quality-assured medications lead patients and physicians to favor branded variants over unbranded generics, particularly due to perceived inconsistent oversight, a trend underscored by Sun Pharmaceutical's Emerging Markets formulation sales reaching US$ 1,114 million with a 7.0% annual increase in fiscal year 2024-2025. Concurrently, the patent expirations of blockbuster pharmaceuticals present significant opportunities for branded generic market entry, allowing manufacturers to leverage brand recognition to capture market share with therapeutically equivalent alternatives, exemplified by Merck's Keytruda and its $29.5 billion in 2024 sales prior to its patent loss, with regulatory bodies like the U.S. FDA actively facilitating new entrants by granting 87 first-time generic drug approvals in 2025.

Market Driver

The expansion of pharmaceutical markets in emerging economies stands as a primary catalyst for the branded generics sector, driven by rising disposable incomes and a growing preference for quality-assured medications. In nations where regulatory oversight of unbranded generics is perceived as inconsistent, patients and physicians often gravitate toward branded variants, viewing them as a safer middle ground between expensive patented drugs and local unbranded commodities. This trend is evident in the financial performance of major industry players operating in these regions, with Sun Pharmaceutical Industries Limited reporting that its Emerging Markets formulation sales reached US$ 1,114 million for the fiscal year 2024-2025, marking a 7.0% annual increase. Simultaneously, the patent expirations of blockbuster pharmaceuticals unlock substantial opportunities for branded generic market entry. As high-value proprietary drugs lose exclusivity, manufacturers are positioned to capture market share by offering therapeutically equivalent alternatives that leverage established brand recognition to compete against both originators and pure commodity generics. An example of this lucrative landscape is the impending loss of exclusivity for major oncology assets; Merck's Keytruda generated $29.5 billion in sales in 2024, a revenue stream that will become a primary target upon its patent expiration. To capitalize on these shifts, regulatory pathways remain active in facilitating new entrants, with the U.S. Food and Drug Administration granting 87 first-time generic drug approvals throughout 2025, ensuring a continuous influx of off-patent therapies into the global market.

Market Challenge

Intense pricing pressure exerted by regulatory bodies and competitive tendering systems constitutes a primary impediment to the expansion of the market. Governments and payers globally are implementing rigorous cost-containment strategies that frequently prioritize the lowest possible acquisition costs over brand differentiation. In this environment, procurement processes often favor unbranded generic options, forcing branded generic manufacturers to lower their prices significantly to remain competitive. This trend creates a market dynamic where the premium positioning of branded generics is systematically eroded, making it difficult for manufacturers to sustain the profit margins necessary for branding and marketing activities. The resulting financial compression restricts the revenue potential for market players despite high volume demand. Manufacturers are compelled to operate within extremely narrow margins, which hampers their ability to reinvest in portfolio expansion or supply chain resilience. Illustrating the severity of this value erosion, according to the Association for Accessible Medicines, in 2024, generic medicines accounted for 90 percent of all prescriptions dispensed in the United States but represented only 13.1 percent of total drug spending. This distinct imbalance between high prescription volume and low revenue share underscores the restrictive economic environment that directly limits the financial growth of the branded generics sector.

Market Trends

Strategic industry consolidation and mergers have emerged as a dominant trend as manufacturers seek to fortify their portfolios against pricing headwinds and competitive saturation. By acquiring targeted assets, companies are able to rapidly integrate high-barrier products such as ophthalmology and biosimilars, thereby scaling operations and securing immediate revenue streams that offset the erosion in traditional generic margins. This inorganic growth strategy allows firms to bypass lengthy development timelines and gain established market access while optimizing their cost structures. According to Sandoz, in March 2024, the company completed the acquisition of the CIMERLI business from Coherus BioSciences for an upfront cash purchase of USD 170 million, explicitly aiming to strengthen its ophthalmology platform and leverage existing commercial infrastructure. Simultaneously, there is an accelerated shift toward complex generics and biosimilars, driven by the need to pivot away from the commoditized oral solids market. Manufacturers are increasingly allocating resources to difficult-to-make formulations, such as injectables and inhalation products, which command higher pricing power and face limited competition compared to standard generics. This transition not only enhances profitability but also aligns with the growing demand for specialized therapies in chronic care segments where brand equity plays a decisive role. Illustrating the commercial success of this focus, according to Amneal Pharmaceuticals, in November 2024, net revenue from the company's generics segment increased 9% to $427 million, a performance primarily attributed to the strong market uptake of new complex product launches and biosimilars.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Inc.
• Dr Reddy's Laboratories Inc.
• Endo International PLC.
• GlaxoSmithKline LLC.
• Pfizer Inc.
• Viatris Inc.
• Apotex Inc.

Report Scope

In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Branded Generics Market, By Drug Class

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti - Hypertensive
• Lipid Lowering Drugs
• Antidepressants
• Antipsychotics
• Antiepileptics
• Others

Branded Generics Market, By Application

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Acute & Chronic Pain
• Gastrointestinal Diseases
• Dermatological Diseases
• Others

Branded Generics Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Branded Generics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.

Available Customizations:

Global Branded Generics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Branded Generics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
  • 5.2.2. By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Acute & Chronic Pain, Gastrointestinal Diseases, Dermatological Diseases, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Branded Generics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Branded Generics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Branded Generics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Branded Generics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Branded Generics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Branded Generics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Branded Generics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Branded Generics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Branded Generics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Branded Generics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Branded Generics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Branded Generics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Branded Generics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Branded Generics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Branded Generics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Branded Generics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Branded Generics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Branded Generics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Branded Generics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Branded Generics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Branded Generics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Branded Generics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Branded Generics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Branded Generics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Branded Generics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lupin Pharmaceuticals Inc.
• 15.3. Sun Pharmaceutical Industries Inc.
• 15.4. Dr Reddy's Laboratories Inc.
• 15.5. Endo International PLC.
• 15.6. GlaxoSmithKline LLC.
• 15.7. Pfizer Inc.
• 15.8. Viatris Inc.
• 15.9. Apotex Inc.

16. Strategic Recommendations

17. About Us & Disclaimer